NCT07454915招募中2 期
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 138
- 试验地点
- 10
- 主要终点
- Proportion of subjects exhibiting virological clearance of HPV16 and histopathological regression of cervical lesions to < CIN2 at Month 6
研究概览
简要总结
The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System) in patients with biopsy-confirmed, human papilloma virus (HPV) 16-associated high grade cervical intraepithelial neoplasia (CIN2/3) as compared to the administration of placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female subjects 18-60 years old with biopsy-confirmed high grade cervical intraepithelial neoplasia (CIN2/3) confirmed by central review.
- •Patients whose cytobrush samples are HPV16+ by Roche Cobas genotyping test. Co-infections with HPV types other than HPV16 are permissible for study entry
- •HIV negative
- •Patients who are able and willing to comply with all study procedures, and with anticipated availability for the planned follow-up period of one year
- •Patients who are of childbearing potential agree to remain sexually abstinent, use methods of contraception (e.g. oral contraception, barrier methods, spermicide, intrauterine device (IUD)), or have a partner who is sterile (i.e., vasectomy) through 6 months.
- •Patients must have adequate organ function at the time of enrollment as defined by the following parameters: white blood cell count >3,000/mcL; lymphocyte number >500/mcL; absolute neutrophil count >1,000/mcL; platelets >90,000/mcL; hemoglobin >9 g/dL; total bilirubin <3 X the institutional limit of normal; aspartate aminotransferase (AST [SGOT]) / alanine aminotransferase (ALT [SGPT]) <3 X the institutional limit of normal; creatinine <2.5X the institutional limit of normal.
排除标准
- •Patients who are attempting pregnancy within 6 months, pregnant, or breastfeeding.
- •Patients with immunodeficiency, or treatment with immunosuppressive medications
- •Administration of any blood product within 3 months of enrollment.
- •Administration of any licensed vaccine within 2 weeks of enrollment (4 weeks for a live vaccine)
- •Participation in a study with an investigational compound or device within 30 days of signing informed consent.
- •History of seizures (unless seizure free for 5 years)
- •Previous cancer history within the past 5 years, except localized skin cancer.
- •Patients who have had chemotherapy, radiation, biological cancer therapy, or other investigational agents within 28 days prior to the first dose of study drug.
- •Patients who have had surgery within 28 days, excluding minor procedures (dental work, skin biopsy, etc).
- •Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing, or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis).
- •Previous cervical conization or LEEP procedure or previous total hysterectomy due to cervical lesions at enrollment
- •High-grade intraepithelial lesions (CIN2/3) encompassing more than 180-degree (more than 2 quarters) of cervix
- •Positive HBV PCR if Hepatitis B surface antigen positive
- •Positive HCV PCR if anti-HCV positive
- •Border of high-grade intraepithelial lesions (CIN2/3) could not be completely observed by colposcope and positive for high grade disease by endocervical curettage.
- •Cervical biopsy and/or ECC of adenocarcinoma in situ (AIS)
- •Pre-biopsy Pap of Atypical Glandular Cells (AGC)/AGC favor neoplasm, squamous cell carcinoma (SCC), or cervical biopsy of CIN2/3 with postmenopausal bleeding
- •Participant has:
- •Less than 2 acceptable potential injection sites for IM injection and electroporation considering the left and right medial deltoid, and anterolateral quadriceps muscles. A site for injection and electroporation is not acceptable if there is inadequate muscle mass to support at least a 19 mm/0.75 inch injection depth or a skinfold thickness measurement of ≥50 mm as assessed using the provided caliper. Eligible injection sites must also be free from tattoos, hypertrophic skin patches, keloids or other skin conditions which could interfere with the administration procedure or subsequent assessment of local reactogenicity.
- •Note: To ensure adequate muscle mass for administrations, for participants with a weight ≤65 kg, potentially eligible administration sites are confined to the outer aspect of the upper thigh (left or right vastus lateralis muscle) (i.e., the left and right medial deltoid are not eligible administration sites).
- •Contraindication to intramsucular injections and blood draws.
- •A metal implant or implantable device within the area of the electroporation injection site at > 2 of the eligible injection sites.
- •A nonremovable electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.
- •Participant is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.
- •Vulnerable participants (e.g., incarcerated individuals, individuals under a legal protection measure).
研究组 & 干预措施
Active
Experimental
PVX4 (pBI-4 DNA vaccine administered via the Intramuscular TriGrid Electroporation Delivery System version 2.0)
干预措施: PVX4 Combination Product (Combination Product)
Placebo
Placebo Comparator
Sodium Chloride 0.9% for injection administered via the Intramuscular TriGrid Electroporation Delivery System version 2.0
干预措施: Placebo Control (Other)
结局指标
主要结局
Proportion of subjects exhibiting virological clearance of HPV16 and histopathological regression of cervical lesions to < CIN2 at Month 6
时间窗: Month 6
The proportion of subjects with histopathologically confirmed HPV16 associated CIN2 or CIN 3 who exhibit virological clearance of HPV16 and regression of cervical lesions to \< CIN 2 at Month 6.
次要结局
- Sustained virological clearance of HPV16(Month 12)
- TDS-IM v2.0 Device Reliability(Week 0, 4, and 8)
研究者
研究点 (10)
Loading locations...
相似试验
尚未招募
1 期
A clinical trial of Quadrivalent Human Papillomavirus (HPV) vaccine in healthy subjects.CTRI/2025/07/090243Cadila Pharmaceuticals Limited24
招募中
4 期
Human papillomavirus vaccine effectiveness study among men who have sex with men2022-502224-49-00Geneeskundige En Gezondheidsdienst Amsterdam730
招募中
2 期
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II TrialNCT07286253Affiliated Cancer Hospital & Institute of Guangzhou Medical University50
尚未招募
2 期
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)Head and Neck CancerOropharyngeal CancerNCT07418034University of Maryland, Baltimore132
招募中
2 期
HPV2-2303 - Phase 2 clinical trial evaluating secondary HPV vaccination after treatment of high-grade cervical lesions2024-513081-19-00Centre Oscar Lambret85